AC
AKBA icon

Allstate Corporation’s Akebia Therapeutics AKBA Stock Holding History

Allstate Corporation’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-19,826
Closed -$50K – 705
2020
Q3 		$50K Buy
19,826
+147
+0.7% +$1.29K ﹤0.01% 661
2020
Q2 		$267K Buy
+19,679
New +$204K 0.01% 603

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Allstate Corporation's AKBA Position: Q4 2020 in Review

Allstate Corporation sold out of Akebia Therapeutics (AKBA) in Q4 2020, closing a stake of 19,826 shares — an estimated $50K sold.

Allstate Corporation first reported a position in AKBA in Q2 2020 and held it in 2 quarters. The position peaked at $267K in Q2 2020. 143 funds tracked by Wall St. Rank hold AKBA as of Q4 2020.

  • Allstate Corporation reported no remaining Akebia Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Allstate Corporation sold 19,826 Akebia Therapeutics shares in Q4 2020, an estimated $50K.
  • Allstate Corporation first reported a position in Akebia Therapeutics in Q2 2020 and held it in 2 quarters.
  • Allstate Corporation's Akebia Therapeutics position peaked at $267K in Q2 2020.
  • 143 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2020.

Based on Allstate Corporation's 13F filing for Q4 2020, filed 12 Feb 2021.